Capricor Therapeutics Shareholders: A Chance to Pursue Securities Fraud Claims

Overview of the Legal Situation

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is currently under scrutiny following allegations of securities fraud. Investors who have suffered significant losses during a particular time frame may have the chance to take the lead in a class action lawsuit invoking these allegations. The law firm Howard G. Smith is spearheading this initiative and has made an announcement entreating eligible investors to comprehend their legal standings as the deadline approaches.

Who is Affected?

Between December 17, 2025, and July 26, 2026, certain misleading statements concerning Capricor’s operations have been called into question. If you are an investor impacted by this situation and suffered losses, it would be prudent to contact legal counsel by the end of September 2026 to preserve your rights and assist in the pursuit of this case.

The Allegations

The core of the accusations lies in the defendant's failure to disclose crucial information regarding the company’s business practices. Investors were allegedly misled about:

1. Changes to the Statistical Analysis Plan: It was claimed that significant alterations were made to an essential plan used to evaluate clinical data for the product Deramiocel without prior agreement from the FDA before the resubmission of the Biologics License Application (BLA).
2. FDA Agreement and Risks: There was a failure to communicate that the FDA did not consent to these modifications, which potentially undermined the credibility of the clinical results provided by the company.
3. Substantial Evidence of Effectiveness: Due to these undisclosed changes, there’s a substantial risk that the FDA might conclude the clinical evidence lacked adequate support for the drug’s effectiveness in treating Duchenne muscular dystrophy.
4. Misleading Positive Statements: The affirmative declarations made by company executives regarding Capricor’s business prospects also lacked a sound basis because they did not consider these significant risks.

The Importance of Timeliness

Investors are encouraged to act promptly if they fit the eligibility criteria to join the class action. By contacting the Law Offices of Howard G. Smith, investors can gain insight into their legal rights and options. The firm has provided multiple contact methods, including phone and email, for investors to seek clarification on their situations. Should you decide to participate, remember, you do not need to take immediate action; however, retaining counsel is crucial for those desiring to be involved.

Conclusion

As the investigation unfolds, shareholders of Capricor Therapeutics must remain vigilant regarding their financial interests. With the deadline to join this class action lawsuit fast approaching, affected individuals should take this opportunity seriously. If you feel you qualify, it’s essential to communicate with legal experts to discuss your options thoroughly. This case not only seeks justice for lost investments but also emphasizes the responsibility of corporations to maintain transparency and integrity in their operations.

For more details or legal assistance, reach out to the Law Offices of Howard G. Smith via phone at (215) 638-4847 or visit their website at howardsmithlaw.com.